Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible α-cell hyperplasia and hyperglucagonemia

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 871-881

  Gu, Wei ^a   Yan, Hai ^a   Winters, Katherine A ^a   Komorowski, Renée ^a   Vonderfecht, Steven ^a   Atangan, Larissa ^a   Sivits, Glenn ^a   Hill, David ^a   Yang, Jie ^a   Bi, Vivian ^a   Shen, Yuqing ^a   Hu, Sylvia ^a   Boone, Tom ^a   Lindberg, Richard A ^a   Véniant, Murielle M ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON RECEPTOR; MONOCLONAL ANTIBODY; ANTIDIABETIC AGENT; GLUCAGON; GLUCOSE; INSULIN;

ARTICLE; DRUG INHIBITION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HYPERGLUCAGONEMIA; HYPOGLYCEMIA; MOUSE; NONHUMAN; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; ANIMAL; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERPLASIA; MALE; METABOLISM; OBESITY; PANCREAS ISLET ALPHA CELL; PATHOLOGY; TACHYPHYLAXIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE; HYPERGLYCEMIA; HYPERPLASIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; OBESITY; RECEPTORS, GLUCAGON; TACHYPHYLAXIS;

EID: 73349089955     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157685     Document Type: Article

References (32)

1. Arion WJ, Canfield WK, Ramos FC, Su ML, Burger HJ, Hemmerle H, Schubert G, Below P, and Herling AW (1998) Chlorogenic acid analogue S 3483: a potent competitive inhibitor of the hepatic and renal glucose-6-phosphatase systems. Arch Biochem Biophys 351:279-285.
2. Bhanot LMW, Sloop KW, Cao JC, Showalter AD, Dodson M, and Monia BP (2006) Reduction of hepatic glucagon receptor expression with an optimized antisense oligonucleotide increased active GLP-1 levels in cynomolgus monkeys without pancreatic alpha cell expansion or hyperplasia. 66th Scientific Sessions; 2007 Jun 9-13; Washington, DC. American Diabetes Association, Alexandria, VA.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, and Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110.
4. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, and Caicedo A (2006) The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 103:2334-2339.
5. Carlson MG, Snead WL, and Campbell PJ (1993) Regulation of free fatty acid metabolism by glucagon. J Clin Endocrinol Metab 77:11-15.
6. Christophe J (1996) Glucagon and its receptor in various tissues. Ann N Y Acad Sci 805:31-42; discussion 42-33.
7. Ciudad C, Camici M, Ahmad Z, Wang Y, DePaoli-Roach AA, and Roach PJ (1984) Control of glycogen synthase phosphorylation in isolated rat hepatocytes by epinephrine, vasopressin and glucagon. Eur J Biochem 142:511-520.
8. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, Ronan J, Liu F, Roy RS, Zhu L, et al. (2007) Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50:142-150.
9. Consoli A, Nurjhan N, Capani F, and Gerich J (1989) Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38:550-557.
10. Dunning BE and Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253-283.
11. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438-1443.
12. Horton JD, Goldstein JL, and Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131.
13. Jiang G and Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671-E678.
14. Keller U, Schnell H, Sonnenberg GE, Gerber PP, and Stauffacher W (1983) Role of glucagon in enhancing ketone body production in ketotic diabetic man. Diabetes 32:387-391.
15. Klain GJ (1977) In vivo effects of glucagon on fatty acid synthesis in fasted and refed rats. J Nutr 107:942-948.
16. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, and Demarest KT (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410-417.
17. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, and Treadway JL (1998) Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci U S A 95:1776-1781.
18. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, and Gerich J (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29.
19. Müller WA, Faloona GR, Aguilar-Parada E, and Unger RH (1970) Abnormal alphacell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109-115.
20. Parker JC, Andrews KM, Allen MR, Stock JL, and McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839-843.
21. Petersen KF and Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024.
22. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, Ding VD, Li Z, Bansal A, Miller C, Cohen SM, et al. (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53:3267-3273.
23. Reed WD, Baab PJ, Hawkins RL, and Ozand PT (1984) The effects of insulin and glucagon on ketone-body turnover. Biochem J 221:439-444.
24. Singhal P, Caumo A, Carey PE, Cobelli C, and Taylor R (2002) Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 283:E275-E283.
25. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571-1581.
26. Sørensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, and Shulman GI (2006) Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55:2843-2848.
27. Srinivasan K and Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125:451-472.
28. Unger RH (1985) Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28:574-578.
29. Unger RH and Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16.
30. van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, and Erion MD (2006) Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 55:1747-1754.
31. Velasquez MT, Kimmel PL, and Michaelis OE 4th (1990) Animal models of spontaneous diabetic kidney disease. Faseb J 4:2850-2859.
32. Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ, et al. (2009) Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 329:1-10.